Total Payments
$305,095
2024 Payments
$7,070
Companies
80
Transactions
2,135
Medicare Patients
2,507
Medicare Billing
$367,275
Payment Breakdown by Category
Other$215,366 (70.6%)
Food & Beverage$43,298 (14.2%)
Consulting$21,308 (7.0%)
Research$17,500 (5.7%)
Travel$7,144 (2.3%)
Education$478.78 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $204,096 | 150 | 66.9% |
| Food and Beverage | $43,298 | 1,847 | 14.2% |
| Consulting Fee | $21,308 | 15 | 7.0% |
| Unspecified | $17,500 | 6 | 5.7% |
| Honoraria | $11,270 | 7 | 3.7% |
| Travel and Lodging | $7,144 | 74 | 2.3% |
| Education | $478.78 | 36 | 0.2% |
Payments by Type
General
$287,595
2,129 transactions
Research
$17,500
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $71,536 | 227 | $0 (2024) |
| Amgen Inc. | $69,065 | 137 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $23,090 | 83 | $0 (2022) |
| ABBVIE INC. | $19,889 | 122 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $19,067 | 113 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $12,587 | 23 | $0 (2021) |
| Allergan, Inc. | $10,781 | 51 | $0 (2022) |
| Neurelis, Inc. | $10,556 | 16 | $0 (2022) |
| Acorda Therapeutics, Inc | $9,184 | 55 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $6,370 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,070 | 268 | EMD Serono, Inc. ($1,381) |
| 2023 | $8,816 | 243 | EMD Serono, Inc. ($2,201) |
| 2022 | $22,533 | 263 | ABBVIE INC. ($9,094) |
| 2021 | $49,309 | 273 | Biohaven Pharmaceuticals, Inc. ($10,228) |
| 2020 | $58,713 | 239 | Teva Pharmaceuticals USA, Inc. ($12,273) |
| 2019 | $56,383 | 302 | Amgen Inc. ($19,721) |
| 2018 | $50,535 | 261 | Teva Pharmaceuticals USA, Inc. ($27,413) |
| 2017 | $51,735 | 286 | Avanir Pharmaceuticals, Inc. ($22,355) |
All Payment Transactions
2,135 individual payment records from CMS Open Payments — Page 1 of 86
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: PAIN | ||||||
| 12/20/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Neuroscience | ||||||
| 12/18/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $28.98 | General |
| 12/18/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/17/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $7.92 | General |
| 12/12/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $37.57 | General |
| Category: Genetic Disease | ||||||
| 12/10/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $202.31 | General |
| 12/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $90.00 | General |
| 12/10/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $27.05 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 12/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| 12/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| 12/06/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: Central Nervous System | ||||||
| 12/06/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/06/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $2.72 | General |
| Category: Central Nervous System | ||||||
| 12/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $91.11 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $33.41 | General |
| Category: AMANTADINE | ||||||
| 12/03/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Life Molecular Imaging Ltd | NEURACEQ (Drug) | Food and Beverage | Cash or cash equivalent | $15.35 | General |
| Category: Diagnostic Tracer | ||||||
| 11/27/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: PAIN | ||||||
| 11/26/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Neurology | ||||||
| 11/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Neuroscience | ||||||
| 11/21/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $17,500 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 614 | 7,135 | $282,353 | $114,746 |
| 2022 | 8 | 607 | 805 | $167,582 | $85,147 |
| 2021 | 7 | 604 | 820 | $135,475 | $87,566 |
| 2020 | 13 | 682 | 921 | $127,628 | $79,816 |
Total Patients
2,507
Total Services
9,681
Medicare Billing
$367,275
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 299 | 467 | $116,750 | $42,357 | 36.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 12 | 6,295 | $47,438 | $27,684 | 58.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 126 | 157 | $47,100 | $20,357 | 43.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 55 | 55 | $19,250 | $8,447 | 43.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 63 | 63 | $18,900 | $7,159 | 37.9% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 13 | 42 | $25,200 | $4,925 | 19.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 24 | 34 | $3,315 | $2,591 | 78.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 22 | $4,400 | $1,225 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 286 | 443 | $77,375 | $38,278 | 49.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 118 | 151 | $37,100 | $20,502 | 55.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 66 | 66 | $21,000 | $10,774 | 51.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 59 | 59 | $15,750 | $6,549 | 41.6% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 11 | 13 | $7,800 | $4,127 | 52.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 35 | $4,700 | $2,134 | 45.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 25 | 26 | $2,535 | $1,853 | 73.1% |
| 95907 | Nerve conduction, 1-2 studies | Office | 2022 | 11 | 12 | $1,322 | $931.50 | 70.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 313 | 500 | $62,500 | $43,235 | 69.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 87 | 106 | $21,200 | $14,959 | 70.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 67 | 67 | $20,100 | $11,912 | 59.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 77 | 77 | $19,250 | $9,601 | 49.9% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Office | 2021 | 11 | 11 | $6,600 | $3,555 | 53.9% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 23 | 30 | $2,925 | $2,340 | 80.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 29 | $2,900 | $1,965 | 67.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 322 | 533 | $55,350 | $37,371 | 67.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 83 | 83 | $21,750 | $13,059 | 60.0% |
About Dr. Norman Gordon, M.D
Dr. Norman Gordon, M.D is a Neurology healthcare provider based in East Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467481648.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Norman Gordon, M.D has received a total of $305,095 in payments from pharmaceutical and medical device companies, with $7,070 received in 2024. These payments were reported across 2,135 transactions from 80 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($204,096).
As a Medicare-enrolled provider, Gordon has provided services to 2,507 Medicare beneficiaries, totaling 9,681 services with total Medicare billing of $367,275. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location East Providence, RI
- Active Since 07/01/2006
- Last Updated 01/18/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1467481648
Products in Payments
- Aimovig (Biological) $49,084
- UBRELVY (Drug) $29,038
- AJOVY (Drug) $26,882
- NUEDEXTA (Drug) $23,065
- COPAXONE (Drug) $20,881
- NUPLAZID (Drug) $19,067
- AJOVY (Biological) $18,322
- NURTEC ODT (Drug) $17,754
- VALTOCO (Drug) $10,556
- INBRIJA (Drug) $8,854
- OXTELLAR XR (Drug) $6,065
- NORTHERA (Drug) $5,361
- GOCOVRI (Drug) $4,886
- RYTARY (Drug) $3,599
- APOKYN (Drug) $2,099
- Leqembi (Drug) $1,993
- Fycompa (Drug) $1,321
- TYSABRI (Biological) $1,265
- APTIOM (Drug) $1,179
- BAFIERTAM (Drug) $1,135
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.